Anindya Roy

Anindya Roy

Co-Founder and CSO at https://www.lila.bio/
Seattle, Washington, United States

Anindya Roy is currently Co-Founder and CSO at Lila Biologics, where he also serves as Executive Officer and Director. He is a chemical biologist and protein designer.

GeekWire and Greater Seattle Partners call for nominations for 2026 Uncommon Thinkers; deadline Sept. 18, winners honored Dec. 10

Nominations for GeekWire’s 2026 Uncommon Thinkers Awards — honoring Seattle-area inventors, scientists, technologists and entrepreneurs — close Friday, Sept. 18 at 11 a.m. PT; winners will be chosen by a judges panel and celebrated at the GeekWire Gala on Dec. 10. The fourth annual program, run with Greater Seattle Partners, seeks nominees who demonstrate innovation, leadership and measurable impact.

Uncommon Thinkers 2025: Solar spacecraft, sci-fi biology, destroying PFAS, beyond AI chatbots, and better social media

On this special episode of the GeekWire Podcast, recorded backstage at the GeekWire Gala at the Showbox Sodo, we sit down with five of the inventors, scientists, and entrepreneurs selected as the Seattle region's 2025 Uncommon Thinkers, in partnership with Greater Seattle Partners. Jeff Thornburg spent years building rocket engines for Elon Musk at SpaceX and Paul Allen at Stratolaunch. Now, as CEO of Portal Space Systems, he's moved past chemical rockets to revive a concept NASA studied decades ago but never pursued — a spacecraft powered by focused sunlight. He calls it a "steam engine for space." Read the…

GeekWire Honors Six 'Uncommon Thinkers' Transforming Industries with Innovative Startups in 2025

GeekWire's third annual 'Uncommon Thinkers' honors six innovators including Anindya Roy, Kiana Ehsani, and Jeff Thornburg, who are leading startups transforming industries with breakthrough technologies in biotech, social media, and space propulsion. These leaders will be celebrated at the GeekWire Gala in Seattle for their creative and mission-driven approaches to solving significant challenges.

Lila Biologics, Nobel Laureate’s Startup, Partners with Eli Lilly to Develop AI-Based Tumor Therapies

Lila Biologics, a startup from Nobel Laureate David Baker's University of Washington lab, is collaborating with Eli Lilly to develop AI-powered tumor-targeted therapies, aiming to deliver a candidate protein for clinical trials within six months. The startup utilizes AI and machine learning platforms to create therapeutic proteins for targeted radiotherapy and long-acting injectable drugs.

Organizations

See all 4
  • Lila Biologics logo
    Lila Biologics Executive Officer, Director 2023–present, Co-founder · current
  • https://www.lila.bio/ Co-Founder and CSO 2023–present · current
  • University of Washington logo
    University of Washington Senior Fellow 2014–2023 · past

Education

  • Arizona State University Doctor of Philosophy (PhD), Chemistry and Biochemistry · 2008–2013
  • Indian Institute of Technology, Kharagpur Master of Science (M.Sc.), Chemistry · 2006–2008
  • University of Calcutta Bachelor's degree · 2003–2006

Online